Over View

ANAX has outpaced with a CAGR of 70 % in 2016-17.

NEURO category contributes to over 60% of our revenues & GYNEC category contributes to 40%

Our product portfolio is primarily focused on therapeutic areas that require the intervention of Physician, Gynecologist & Specialist doctors such as Diabetologists, Endocrinologists, Neurologist & Psychiatrist.